- Trial phase
- Phase 1/2 (IND cleared, not yet enrolling)
- Time to market
- Unknown; Phase 1/2 enrollment begins H2 2026. If successful, a registrational trial and potential approval would likely be several years away (2029+).
- Why 2/10
- IOV-5001 received FDA IND clearance on June 1, 2026, and a Phase 1/2 basket trial will begin enrolling in H2 2026. There is no near-term binary catalyst: initial safety/efficacy readouts from a Phase 1/2 trial are likely 12+ months away. This is one of several pipeline programs at a company whose valuation is primarily driven by the commercial launch of Amtagvi.
IOV-5001 is too early-stage to drive IOVA's share price in the next 12 months. Investors should focus on Amtagvi revenue growth (FY26 guidance $350M-$370M), the TILVANCE-301 Phase 3 frontline melanoma readout, and IOV-LUN-202 NSCLC registrational data as the primary value drivers. IOV-5001 is a pipeline story for 2028+.
Price Chart
Executive Summary
IOV-5001 is Iovance Biotherapeutics' next-generation, IL-12-tethered TIL therapy, designed to expand the company's TIL platform beyond melanoma into larger solid-tumor indications (colorectal, breast, and others representing 100K+ annual U.S. deaths). The FDA cleared its IND on June 1, 2026, and a Phase 1/2 basket trial begins enrollment in H2 2026. Preclinical data showed superior antitumor activity vs. standard TIL. However, IOV-5001 is one of several pipeline assets (IOV-4001, IOV-3001) at a company whose current market value is driven overwhelmingly by the commercial ramp of Amtagvi (lifileucel) for advanced melanoma. With no near-term binary catalyst, IOV-5001 is not a material stock driver for IOVA in the next 12 months.
How It Works
IOV-5001 is a personalized cell therapy made from a patient's own immune cells (TILs) that are extracted from their tumor, genetically enhanced in the lab, and infused back. The genetic modification adds a safety switch: the cells only produce IL-12 (a potent immune-signaling protein) when they encounter tumor cells, and the IL-12 is anchored to the cell surface so it doesn't leak into the bloodstream. This is designed to convert 'cold' tumors that don't respond to immunotherapy into 'hot' ones that do, while avoiding the severe side effects of systemic IL-12.
Trial Status
FDA cleared the IND on June 1, 2026. A Phase 1/2 basket trial (no formal NCT number yet) will begin enrolling in the second half of 2026. The trial will evaluate a one-time IOV-5001 regimen without IL-2 across advanced colorectal, triple-negative breast, ER-low breast, and other solid tumors. Preclinical data presented at AACR 2025 and SITC 2024 showed enhanced antitumor activity vs. unmodified TIL.
The Two-Sided Case
Upcoming Catalysts
- Phase 1/2 basket trial initiation (enrollment start) in H2 2026
- Potential early safety and pharmacokinetic data at medical conferences in 2027
- Possible IND updates in quarterly corporate updates or earnings calls
Source Filing
The SecBot filing or press-release report that triggered this drug report:
IOVANCE BIOTHERAPEUTICS, INC. 8-K IOVA ·Originating report